))
S02E05 Rebounds are not limited to basketball. Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study: Continued Versus Washout.
Manage episode 338694098 series 3011762
Conteúdo fornecido por Women in Ophthalmology. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Women in Ophthalmology ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
Rebounds are not limited to basketball. Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study: Continued Versus Washout.
Rebounds are not limited to basketball. Dr Sarah Hull examines the rebound effect in the Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study. What are the outcomes of continued atropine treatment, and what is the ideal concentration?
Sarah Hull is a UK-trained Ophthalmologist who completed a PhD in paediatric retinal genetics at UCL and Moorfields in 2016. She has been living in New Zealand since 2018, working as a consultant Ophthalmologist specialising in paediatrics, strabismus and genetics at Auckland District Health Board and Auckland Eye. She is also a Senior Lecturer at Auckland University. Her research focuses on inherited eye disease as well as optic neuropathies.
20 episódios
Compartilhar
